|Systematic (IUPAC) name|
|Licence data||EMA: , US FDA:|
|Protein binding||55% and 66% for the (+)-R and (–)-S enantiomers, respectively|
|Metabolism||Hepatic (minimally via CYP2C19-mediated 5-hydroxylation; mostly via non-enzymatic hydrolysis at the four amide sites)|
|Half-life||5-7.5 hours (dose-dependent)|
|(what is this?)|
Thalidomide was first marketed in 1957 in West Germany under the trade-name Contergan. The German drug company Chemie Grünenthal (now Grünenthal) developed and sold the drug. Primarily prescribed as a sedative or hypnotic, thalidomide also claimed to cure “anxiety, insomnia, gastritis, and tension". Afterwards, it was used against nausea and to alleviate morning sickness in pregnant women. Thalidomide became an over the counter drug in Germany on October 1, 1957. Shortly after the drug was sold in Germany, between 5,000 and 7,000 infants were born with phocomelia (malformation of the limbs). Only 40% of these children survived. Throughout the world, about 10,000 cases were reported of infants with phocomelia due to thalidomide; only 50% of the 10,000 survived. Those subjected to thalidomide while in the womb experienced limb deficiencies in a way that the long limbs either were not developed or presented themselves as stumps. Other effects included deformed eyes and hearts, deformed alimentary and urinary tracts, blindness and deafness. The negative effects of thalidomide led to the development of more structured drug regulations and control over drug use and development.
- 1 Medical uses
- 2 Adverse effects
- 3 Mechanism of action
- 4 Pharmacokinetics
- 5 History
- 6 Thalidomide analogs
- 7 Society and culture
- 8 Research
- 9 See also
- 10 References
- 11 Further reading
- 12 External links
Thalidomide is used for a number of conditions including: erythema nodosum leprosum, multiple myeloma and a number of other cancers, for some symptoms of HIV/AIDS, Crohn's disease, sarcoidosis, graft-versus-host disease, rheumatoid arthritis and a number of skin conditions that have not responded to usual treatment. However, there is no good evidence that thalidomide or lenalidomide is useful to bring about or maintain remission in Crohn's disease.
In 1964, Israeli physician Jacob Sheskin administered thalidomide to a patient critically ill with leprosy. The patient exhibited erythema nodosum leprosum (ENL), a painful skin condition, one of the complications of leprosy. This was attempted despite the ban on thalidomide's use, but results were favourable: the patient slept for hours and was able to get out of bed without aid upon awakening. A clinical trial studying the use of thalidomide in leprosy soon followed.
Thalidomide has been used by Brazilian physicians as the drug of choice for the treatment of severe ENL since 1965, and by 1996, at least 33 cases of thalidomide embryopathy were recorded in people born in Brazil after 1965. Since 1994, the production, dispensing, and prescription of thalidomide have been strictly controlled, requiring women to use two forms of birth control and submit to regular pregnancy tests. Despite this, cases of thalidomide embryopathy continue, with at least 100 cases identified in Brazil between 2005 and 2010. 5.8 million thalidomide pills were distributed throughout Brazil in this time period, largely to poor Brazilians in areas with poor access to healthcare, and these cases have occurred despite the controls.
In 1998 the FDA approved the drug's use in the treatment of ENL. Because of thalidomide's potential for causing birth defects, the drug may be distributed only under tightly controlled conditions. The FDA required that Celgene Corporation, which planned to market thalidomide under the brand name Thalomid, establish a system for thalidomide education and prescribing safety (STEPS) oversight program. The conditions required under the program include limiting prescription and dispensing rights to authorized prescribers and pharmacies only, keeping a registry of all patients prescribed thalidomide, providing extensive patient education about the risks associated with the drug, and providing periodic pregnancy tests for women who take the drug.
More recently, the World Health Organisation (WHO) has stated:
"The WHO does not recommend the use of thalidomide in leprosy as experience has shown that it is virtually impossible to develop and implement a fool-proof surveillance mechanism to combat misuse of the drug. The drug clofazimine is now a component of the multidrug therapy (MDT), introduced by WHO in 1981 as the standard treatment for leprosy and now supplied free of charge to all patients worldwide."
Thalidomide was initially tested in humans as a single agent for the treatment of multiple myeloma due to its anti-angiogenic activity. The early foundation for this work was laid out in a 1993 keynote lecture at the American Society of Hematology by Dr. Folkman when he hypothesized that all blood borne malignancies are angiogenesis-dependent, based upon his discovery that the levels of the angiogenic growth factor FGF were elevated in the urine of patients with leukaemia. Further studies in his lab showed efficacy with the angiogenesis inhibitor TNP-470 in mouse models of leukaemia. Additionally, in 1994 Vacca had shown a fivefold increase in angiogenesis in the bone marrow of multiple myeloma patients. When the family of a patient with late stage multiple myeloma requested any possible help from Dr. Folkman in 1997, he attempted to obtain TNP-470 as a therapy. However TNP-470 could not be obtained outside of the ongoing clinical trial and thus Dr. D'Amato suggested that thalidomide be used instead for this patient. A small study was then initiated with thalidomide for this patient and several others by Dr. Bart Barlogie with dramatic effects. Since then, many studies have shown that thalidomide, in combination with dexamethasone, has increased the survival of multiple myeloma patients.
In the 2000s, the combination of thalidomide and dexamethasone, often in combination with melphalan, became one of the most common regimens for patients with newly diagnosed multiple myeloma. Thalidomide may also cause side effects, such as polyneuropathy, fatigue, skin rash, and venous thromboembolism (VTE), or blood clots, which could lead to stroke or myocardial infarction.
In 2006 the U.S. Food and Drug Administration granted accelerated approval for thalidomide in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma patients. The FDA approval came seven years after the first reports of efficacy in the medical literature
- Somnolence (drowsiness; ~40%)
- Edema (~60%)
- Hypotension (low blood pressure)
- Haematuria (blood in the urine)
- Arthralgia (joint pain)
- Myalgia (muscle aches)
- Increased bilirubin
- Neutropenia (~30%)
- Leucopenia (~15-40%)
- Peripheral neuropathy†
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
- Dyspnoea (shortness of breath/breathlessness)
Rare (may affect up to 1 in 1,000 people):
- Increased appetite
- Bradycardia (low heart rate)
- Tachycardia (high heart rate)
- Cardiac arrhythmia
- Deep vein thrombosis
Very rare (may affect up to 1 in 10,000 people):
- Reduced libido
- Orthostatic hypotension
- Thromboembolic events
- Intestinal obstruction
- Pruritus (itchiness)
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Facial oedema
- Photosensitivity (light sensitivity)
- Menstruation abnormalities
† Peripheral neuropathy may be irreversible and usually results from chronic (usually a matter of months) exposure to thalidomide.
Animal studies have failed to demonstrate any carcinogenicity even when rats and mice were exposed to up to 11 times the therapeutic dose of thalidomide. Despite this there have been some concerns that it may cause secondary malignancies in patients with multiple myeloma. The FDA has issued a statement that it is investigating these concerns. Some clinical trials have supported this claim and the major secondary malignancy that thalidomide is associated with is acute myeloid leukaemia. The MHRA of the UK and Health Canada of Canada have also issued warnings to healthcare professionals regarding the risk of secondary malignancies due to thalidomide exposure.
- Known hypersensitivity to thalidomide
- Pregnancy or breastfeeding
- Patient age < 12 years
- Patients who are unable or unwilling to comply with required contraceptive measures
There are no expected pharmacokinetic interactions between thalidomide and other medicines due to its neutral effects on p-glycoprotein and P450 cytochromes. It may interact with sedatives due to its sedative action. It may also interact with bradycardic agents due to its bradycardia-inducing effects. The risk of peripheral neuropathy may be increased by concomitant treatment with other agents known to cause peripheral neuropathy. The risk of venous thromboembolisms with thalidomide seems to be increased when patients are treated with oral contraceptives or other cytotoxic agents (including doxorubicin and melphalan) concurrently. Thalidomide may interfere with the contraceptive effects of various contraceptives and hence it is advised that women of reproductive age use at least two different means of contraception to ensure that no child will be conceived while they are receiving thalidomide.
Eighteen cases of overdoses have been reported to date with doses of up to 14.4 g without any reported fatalities. No specific antidote for overdoses exists and treatment is purely supportive.
Mechanism of action
The precise mechanism of action for thalidomide is unknown, but possible mechanisms include anti-angiogenic and oxidative stress-inducing effects. It also inhibits TNF-α, IL-6, IL-10 and IL-12 production, modulates the production of IFN-γ and enhances the production of IL-2, IL-4 and IL-5 by immune cells. It increases lymphocyte count, costimulates T cells and modulates natural killer cell cytotoxicity. It also inhibits NF-κB and COX-2 activity.
In 1990, a group of researchers in Brazil noted that TNF alpha levels went up in leprosy reactional states and observed that TNF levels decreased in some patients on treatment with thalidomide, hence potentially explaining the efficacy of thalidomide in treating ENL.
The mechanism of thalidomide's teratogenic action has led to over 2000 research papers and the proposal of 15 or 16 plausible mechanisms. Angiogenesis is critical during limb development of the foetus. Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo. Teratogenic analogs inhibit angiogenesis whereas nonteratogenic analogs do not inhibit angiogenesis. In 2009, research by other groups confirmed "conclusively that loss of newly formed blood vessels is the primary cause of thalidomide teratogenesis, and developing limbs are particularly susceptible because of their relatively immature, highly angiogenic vessel network". Thus the accepted theory is that inhibition of angiogenesis is the mechanism of teratogenicity as originally proposed by D'Amato in 1994.
Thalidomide is racemic; the individual enantiomers can racemize due to the acidic hydrogen at the chiral centre, which is the carbon of the glutarimide ring bonded to the phthalimide substituent. The racemization process can occur in vivo so that any plan to administer a purified single enantiomer to avoid the teratogenic effects will most likely be in vain.
Inactivation of the protein cereblon
Thalidomide binds to and inactivates the protein cereblon, which is important in limb formation and for the proliferative capacity of myeloma cells. This was confirmed in studies that reduced the production of cereblon in developing chick and zebrafish embryos using genetic techniques. These embryos had defects similar to those treated with thalidomide. However, the finding that cereblon inhibition is responsible for the teratgenic activity of thalidomide in the chick and zebrafish was cast into doubt due to a recent report that pomalidomide, a more potent thalidomide analog, does not cause teratogenic effects in these same model systems despite the fact that it is a stronger inhibitor of cereblon than thalidomide.
|This section does not cite any references or sources. (March 2014)|
|Cmax||Tmax||Half-life||Bioavailability||Plasma protein binding||Volume of distribution||Urine clearance||Excretion|
|1.15-3.2 µg/mL||3–6 hours||5–7 hours||90%||55-66%||122 L||1.15 mL/min||Urine (91.9%)|
Thalidomide was developed by German pharmaceutical company Chemie Grünenthal (now Grünenthal GmbH). After obtaining a twenty-year patent in April 1954, Chemie Grünenthal started clinical trials and as early as November 1956 marketed thalidomide for the treatment of respiratory infections under the trade name Grippex, a combination drug that contained thalidomide, quinine, vitamin C, phenactin and acetylsalicylic-acid.
Researchers at Chemie Grünenthal also found that thalidomide was a particularly effective antiemetic that had an inhibitory effect on morning sickness. Hence, on October 1, 1957, the company launched thalidomide and began aggressively marketing it under the trade name Contergan®. It was proclaimed a "wonder drug" for insomnia, coughs, colds and headaches.
During this time period, the use of medications during pregnancy was not strictly controlled, and drugs were not thoroughly tested for potential harm to the foetus. Thousands of pregnant women took the drug to relieve their symptoms. At the time of the drug's development, scientists did not believe any drug taken by a pregnant woman could pass across the placental barrier and harm the developing foetus, even though the effect of alcohol on foetal development had been documented by case studies on alcoholic mothers since at least 1957. There soon appeared reports of findings of abnormalities in children being born, traced back to the use of the drug thalidomide. In late 1959, it was noticed that peripheral neuritis developed in patients who took the drug over a period of time, and it was only after this point that thalidomide ceased to be provided over-the-counter.
Hence, while initially considered safe, the drug was responsible for teratogenic deformities in children born after their mothers used it during pregnancies, prior to the third trimester. In November 1961, thalidomide was taken off the market due to massive pressure from the press and public. Experts estimate that the drug thalidomide led to the death of approximately 2,000 children and serious birth defects in more than 10,000 children, about 5,000 of them in the Federal Republic of Germany (then most commonly known as West Germany). The regulatory authorities in the German Democratic Republic, as the former communist East Germany was called, did not approve thalidomide. One reason for the initially unobserved side effects of the drug and the subsequent approval in Germany was that at that time drugs did not have to be tested for teratogenic effects. They had been tested on rodents only, as was usual at the time.
Thalidomide became one of the most successful prescription drugs in the history of medicine. In the UK, the British pharmaceutical company The Distillers Company (Biochemicals) Ltd, a subsidiary of Distillers Co. Ltd. (now part of Diageo plc), marketed thalidomide under the brand name Distaval® as a remedy for morning sickness throughout the United Kingdom, Australia and New Zealand. Their advertisement claimed that "Distaval can be given with complete safety to pregnant women and nursing mothers without adverse effect on mother or child...Outstandingly safe Distaval has been prescribed for nearly three years in this country."[dead link] Around the world, more and more pharmaceutical companies started to produce and market the drug under license from Chemie Grünenthal. By the mid 1950s, 14 pharmaceutical companies were marketing thalidomide in 46 countries under 37 (some reports suggest 51) different trade names.
In the U.S., representatives from Chemie Grünenthal approached Smith, Kline & French (SKF), now GlaxoSmithKline (GSK) with a request to market and distribute the drug in North America. A newly discovered memorandum (found hidden in 2010 in the archives of the U.S. Food and Drug Administration (FDA)) shows that, as part of their in-licensing approach, Smith, Kline and French conducted animal tests and ran a clinical trial of the drug in the United States involving 875 people, including pregnant women, in 1956–57. In 1956, researchers at SKF involved in clinical trials noted that even when used in very high doses, thalidomide could not induce sleep in mice. And when administered at doses 50 to 650 times larger than that claimed by Chemie Grunenthal to be "sleep inducing", the researchers could still not achieve the hypnotic effect in animals that it had on humans. After completion of the trial, and based on reasons kept hidden for decades, SKF declined to commercialize the drug. Later, Chemie Grünenthal, in 1958, reached an agreement with William S Merrell Company in Cincinnati, Ohio, (later Richardson-Merrell, now part of Sanofi), to market and distribute thalidomide throughout the United States.[dead link]
The U.S FDA refused to approve thalidomide for marketing and distribution. However, the drug was distributed in large quantities for testing purposes, after the American distributor and manufacturer Richardson-Merrell had applied for its approval in September 1960. The official in charge of the FDA, Frances Oldham Kelsey, did not rely on information from the company which did not include any test results. Richardson-Merrell was called on to perform tests and report the results. The company refused and demanded approval six times, and was refused each time. Nevertheless, a total of 17 children with thalidomide-induced malformations were born.
In Canada, the history of the drug thalidomide dates back to April 1, 1961. There were many different forms sold, with the most common variant being Talimol. Two months after Talimol went on sale, pharmaceutical companies sent physicians letters warning about the risk of birth defects. It was not until March 2, 1962, that both drugs were banned from the Canadian market by the FDD, and soon afterward physicians were warned to destroy their supplies.
The exploration of the antiangiogenic and immunomodulatory activities of thalidomide has led to the study and creation of thalidomide analogs. Celgene has sponsored numerous clinical trials with analogues to thalidomide, such as lenalidomide, that are substantially more powerful and have fewer side effects — except for greater myelosuppression. In 2005, Celgene received FDA approval for lenalidomide (Revlimid) as the first commercially useful derivative. Revlimid is available only in a restricted distribution setting to avoid its use during pregnancy. Further studies are being conducted to find safer compounds with useful qualities. Another more potent analog, pomalidomide, is now FDA approved. These thalidomide analogs can be used to treat different diseases, or used in a regimen to fight two conditions.
Interest turned to Pomalidomide, a derivative of thalidomide marketed by Celgene. It is a very active anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It received a similar approval from the European Commission in August 2013, and is expected to be marketed in Europe under the brand name Imnovid.
Society and culture
Regulatory approved uses
|Labelled indication||USA (FDA)(date)||Australia (TGA) (date)||European Union (EMA) (date) ||Literature support/Notes|
|Crohn's disease||Orphan-only||No||No||Children and adolescents (in a small randomised clinical trial) and adults (in open-label clinical trials).|
|Erythema nodosum leprosum (ENL)||Yes (1998)||Yes (2009)||No||Some literature support, including at least two randomised placebo-controlled trials.|
|Graft versus host disease (GVHD)||Orphan-only||No||No||Limited literature support.|
|Hematopoietic Stem Cell Transplantation||Orphan-only||No||No|
|HIV-associated wasting syndrome||Orphan-only||No||No|
|Kaposi's sarcoma (KS)||Orphan-only||No||No||Rare soft tissue cancer most commonly seen in the immunocompromised. Caused by the Kaposi's sarcoma-associated herpesvirus (KSHV). A phase II study has confirmed its efficacy.|
|Multiple myeloma||Yes (2006)||Yes (2009)||Yes (2008)||Numerous clinical trials have confirmed its efficacy, most often when used in combination with other medications.|
|Mycobacterial infection||Orphan-only||No||No||Mycobacterial infections include lepropsy, tuberculosis and mycobacterium avium complex (MAC) infections.|
|Primary brain malignancy||Orphan-only||No||No|
|Recurrent aphthous ulcers||Orphan-only||No||No|
Birth defects crisis
In the late 1950s and early 1960s, more than 10,000 children in 46 countries were born with deformities such as phocomelia as a consequence of thalidomide use. It is not known exactly how many worldwide victims of the drug there have been, although estimates range from 10,000 to 20,000. Despite the side effects, thalidomide was sold in pharmacies in Canada until 1962; Canada was the last country to end sales of the drug.
In the United Kingdom, the drug was licensed in 1958 and withdrawn in 1961. Of the approximately 2,000 babies born with defects, around half died within a few months and 466 survived to at least 2010.
The Australian obstetrician William McBride and the German paediatrician Widukind Lenz suspected a link between birth defects and the drug, a theory Lenz proved in 1961. McBride was later awarded a number of honors, including a medal and prize money by L'Institut de la Vie in Paris.
In East Germany, the head of the central pharmacy control commission, Friedrich Jung, suspected an antivitaminic effect of thalidomide as derivative of glutamic acid. Meanwhile, in West Germany, it took some time before the increase in dysmelia at the end of the 1950s was connected with thalidomide. In 1958 Karl Beck, a former pediatric doctor in Bayreuth wrote an article in a local newspaper claiming a relationship between nuclear weapons testing and cases of dysmelia in children. Based on this, FDP whip Erich Mende requested an official statement from the federal government. For statistical reasons, the main data series used to research dysmelia cases started by chance at the same time as the approval date for thalidomide. After the Nazi regime with its Law for the Prevention of Hereditarily Diseased Offspring used mandatory statistical monitoring to commit various crimes, western Germany had been very reluctant to monitor congenital disorders in a similarly strict way. The parliamentary report rejected any relation with radioactivity and the abnormal increase of dysmelia. Also the DFG research project installed after the Mende request was not helpful. The project was led by pathologist Franz Büchner who ran the project to propagate his teratological theory. Büchner saw lack of healthy nutrition and behavior of the mothers as being more important than genetic reasons.Furthermore, it took a while to install a Surgeon General in Germany; the Federal Ministry of Health (Germany) was not founded until 1962, some months after thalidomide was banned from the market. In Germany approximately 2,500 thalidomide babies were born.
Several countries either restricted the drug's use or never approved it. Ingeborg Eichler, a member of the Austrian pharmaceutical admission conference, enforced thalidomide (tradename Softenon) being sold under the rules of prescription medication and as a result relatively few affected children were born in Austria and Switzerland. In the United States, pharmacologist Frances Oldham Kelsey M.D. withstood pressure from the Richardson-Merrell company and refused Food and Drug Administration (FDA) approval to market thalidomide, saying further studies were needed. This reduced the impact of thalidomide in United States patients. Although thalidomide was never approved for sale in the United States at the time, millions of tablets had been distributed to physicians during a clinical testing program. It was impossible to know how many pregnant women had been given the drug to help alleviate morning sickness or as a sedative.
Aftermath of scandal
For correctly denying the application despite the pressure from Richardson-Merrell, Kelsey eventually received the President's Award for Distinguished Federal Civilian Service at a 1962 ceremony with President John F. Kennedy. In September 2010, the FDA honored Kelsey with the first Kelsey award. The award, given annually to an FDA staff member, came 50 years after Kelsey, then a new medical officer at the agency, first reviewed the application from the William S. Merrell Company of Cincinnati.
In 1968, a large criminal trial began in Germany, charging several Grünenthal officials with negligent homicide and injury. After Grünenthal settled with the victims in April 1970, the trial ended in December 1970 with no finding of guilt. As part of the settlement, Grünenthal paid 100 million DM into a special foundation; the German government added 320 million DM. The foundation paid victims a one-time sum of 2,500-25,000 DM (depending on severity of disability) and a monthly stipend of 100-450 DM. The monthly stipends have since been raised substantially and are now paid entirely by the government (as the foundation had run out of money). Grünenthal paid another 50 million Euros into the foundation in 2008.
The numerous reports of malformations in babies brought about the awareness of the side effects of the drug on pregnant women. The birth defects caused by the drug thalidomide can range from moderate malformation to more severe forms. Possible birth defects include phocomelia, dysmelia, amelia, bone hypoplasticity, and other congenital defects affecting the ear, heart, or internal organs. Franks et al. looked at how the drug affected newborn babies, the severity of their deformities, and reviewed the drug in its early years. Webb in 1963 also reviewed the history of the drug and the different forms of birth defects it had caused. “The most common form of birth defects from thalidomide is shortened limbs, with the arms being more frequently affected. This syndrome is the presence of deformities of the long bones of the limbs resulting in shortening and other abnormalities.”
In 1968, after a long campaign by The Sunday Times, a compensation settlement for the UK victims was reached with Distillers Company (now part of Diageo), which had distributed the drug in the UK. This compensation, which is distributed by the Thalidomide Trust in the UK, was substantially increased by Diageo in 2005. The UK Government gave survivors a grant of £20 million, to be distributed through the Thalidomide Trust, in December 2009.
Melbourne woman Lynette Rowe, who was born without limbs, is leading an Australian class action lawsuit against the drug's manufacturer, Grünenthal, which fought to have the case heard in Germany. The Victorian Supreme Court dismissed Grünenthal's application in 2012, and the case was heard in Australia. More than a hundred Australian thalidomide survivors are involved in the class action, according to Rowe's lawyer. On 17 July 2012, Lynette Rowe was awarded an out-of-court settlement, believed to be in the millions of dollars and paving the way for class action victims to receive further compensation.
On 31 August 2012, Grünenthal chief executive Harald F. Stock, PhD, who served as the Chief Executive Officer of Grünenthal GmbH from January 2009 to May 28, 2013 and was also a Member of Executive Board until May 28, 2013, apologized for the first time for producing the drug and remaining silent about the birth defects. At a ceremony, Stock unveiled a statue of a disabled child to symbolize those harmed by thalidomide and apologized for not trying to reach out to victims for over 50 years. At the time of the apology, there were 5,000 to 6,000 sufferers still alive. Victim advocates called the apology "insulting" and "too little, too late", and criticized the company for not compensating victims. They also criticized the company for their claim that no one could have known the harm the drug caused, arguing that there were plenty of red flags at the time.
The drug thalidomide's birth defects in children affected many people's lives, and from these events came the formation of the group called The Thalidomide Victims Association of Canada, a group of 120 Canadian survivors. Their goal was to prevent future usage of drugs that could be of potential harm to mothers and babies. The members from the thalidomide victims association were involved in the STEPS program, which aimed to prevent teratogenicity.
The effects of thalidomide increased fears regarding the safety of pharmaceutical drugs. The Society of Toxicology of Canada was formed after the effects of thalidomide were made public, focusing on toxicology as a discipline separate from pharmacology. The need for the testing and approval of the toxins in certain pharmaceutical drugs became more important after the disaster. The Society of Toxicology of Canada is responsible for the Conservation Environment Protection Act, focusing on researching the impact to human health of chemical substances. Thalidomide brought on changes in the way drugs are tested, what type of drugs are used during pregnancy, and increased the awareness of potential side effects of drugs.
Notable people affected
- Lorraine Mercer, born with phocomelia of both arms and legs, is the only Thalidomide survivor to carry the Olympic Torch UK 2012
- Mat Fraser, musician, actor and performance artist born with phocomelia of both arms
- Alvin Law, radio broadcaster, born without arms
- Tony Meléndez, award-winning singer and guitarist who plays with his feet and has been recognized by Pope John Paul II and U.S. President Ronald Reagan
- Thomas Quasthoff, an internationally acclaimed bass-baritone, who describes himself: "1.34 meters tall, short arms, seven fingers — four right, three left — large, relatively well-formed head, brown eyes, distinctive lips; profession: singer"
- Niko von Glasow produced a documentary called "NoBody's Perfect", based on the lives of 12 people affected by the drug, which was released in 2008
- Terry Wiles, born with phocomelia of both arms and legs, has become known internationally through the television drama On Giant's Shoulders and the best-selling book of the same name
Change in drug regulations
The disaster prompted many countries to introduce tougher rules for the testing and licensing of drugs, such as the Kefauver Harris Amendment (U.S.) and Directive 65/65/EEC1 (E.U.). In the United States, the new regulations strengthened the FDA, among other ways, by requiring applicants to prove efficacy and to disclose all side-effects encountered in testing. The FDA subsequently initiated the Drug Efficacy Study Implementation to reclassify drugs already on the market.
Investigational uses include:
- AIDS wasting syndrome, associated diarrhoea and Kaposi's sarcoma.
- Renal cell carcinoma (RCC)
- Glioblastoma multiforme
- Prostate cancer
- Colorectal cancer
- Crohn's disease
- Rheumatoid arthritis
- Behcet's syndrome
- Breast cancer
- Head and neck cancer
- Ovarian cancer
- Chronic heart failure
- Graft-versus-host disease
- Immunomodulatory drug
- Discovery and development of thalidomide and its analogs
- Drug of last resort
- Health crisis
- Holt-Oram syndrome
- Category:People with phocomelia
- Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS et al. (2004). "Clinical pharmacokinetics of thalidomide". Clin Pharmacokinet 43 (5): 311–27. doi:10.2165/00003088-200443050-00004. PMID 15080764.
- "Thalidomide". Oxford English Dictionary (3rd ed.). Oxford University Press. September 2005.
- Miller, Marylin T. (1991). "Thalidomide Embryopathy: A Model for the Study of Congenital Incomitant Horizontal Strabismus". Transaction of the American Ophthalmological Society 81: 623–674.
- Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the "War" Against Cancer - Onco'Zine - The International Cancer Network (November 30, 2013)[dead link]
- Cuthbert, Alan (2001, 2003). The Oxford Companion to the Body. Oxford University Press. Retrieved 26 February 2012. Check date values in:
- Heaton, C. A. (1994). The Chemical Industry. Springer. p. 40. ISBN 0-7514-0018-1.
- "Thalidomide". The American Society of Health-System Pharmacists. Retrieved June 2014.
- Srinivasan R, Akobeng AK (Apr 15, 2009). "Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007350. doi:10.1002/14651858.CD007350.pub2. PMID 19370684.
- Akobeng AK, Stokkers PC (Apr 15, 2009). "Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007351. doi:10.1002/14651858.CD007351.pub2. PMID 19370685.
- Silverman WA (August 2002). "The schizophrenic career of a 'monster drug'". Pediatrics 110 (2 Pt 1): 404–6. doi:10.1542/peds.110.2.404. PMID 12165600.
- Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J et al. (December 1996). "Thalidomide, a current teratogen in South America". Teratology 54 (6): 273–7. doi:10.1002/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-# (inactive 2015-01-09). PMID 9098920.
- Paumgartten FJ, Chahoud I (July 2006). "Thalidomide embryopathy cases in Brazil after 1965". Reprod. Toxicol. 22 (1): 1–2. doi:10.1016/j.reprotox.2005.11.007. PMID 16427249.
- Correio Braziliense (January 2006). "Talidomida volta a assustar".[dead link]
- Crawford, Angus (23 July 2013). "Brazil's new generation of Thalidomide babies". BBC News.
- Sheryl Gay Stolberg (17 July 1998). "Thalidomide Approved to Treat Leprosy, With Other Uses Seen". New York Times. Retrieved 8 January 2012.
- Anon. "Use of thalidomide in leprosy". WHO:leprosy elimination. WHO. Retrieved 22 April 2010.
- Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. (November 1999). "Antitumor activity of thalidomide in refractory multiple myeloma". N. Engl. J. Med. 341 (21): 1565–71. doi:10.1056/NEJM199911183412102. PMID 10564685.
- Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (March 1994). "Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers". J. Natl. Cancer Inst. 86 (5): 356–61. doi:10.1093/jnci/86.5.356. PMID 7508518.
- Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. (July 1994). "Bone marrow angiogenesis and progression in multiple myeloma". Br. J. Haematol. 87 (3): 503–8. doi:10.1111/j.1365-2141.1994.tb08304.x. PMID 7527645.
- David Altman (2013-04-02). "From thalidomide to Pomalyst: Better living through chemistry — Vector". Vectorblog.org. Retrieved 2013-05-22.
- Gieseler F (June 2008). "Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates". Thromb. Haemost. 99 (6): 1001–7. doi:10.1160/TH08-01-0009. PMID 18521500.
- Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M (July 2006). "State of the art therapy in multiple myeloma and future perspectives". Eur. J. Cancer 42 (11): 1591–600. doi:10.1016/j.ejca.2005.11.040. PMID 16815703. Vancouver style error (help)
- Haas PS, Denz U, Ihorst G, Engelhardt M (April 2008). "Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses". Eur. J. Haematol. 80 (4): 303–9. doi:10.1111/j.1600-0609.2007.01022.x. PMID 18182082.
- Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW et al. (December 2006). "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer". JAMA 296 (21): 2558–60. doi:10.1001/jama.296.21.2558-c. PMID 17148721.
- "FDA Approval for Thalidomide". National Cancer Institute. Retrieved 8 January 2012.
- Desikan R, Munsi N, Zeldis J (1999). "Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease". Blood 94 (Suppl. 1): 603a–603a.[verification needed]
- "THALOMID (thalidomide) capsule [Celgene Corporation]". DailyMed. Celgene Corporation. November 2013. Retrieved 17 January 2014.
- "Thalomid (thalidomide) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 17 January 2014.
- "Thalidomide Celgene 50 mg Hard Capsules". electronic Medicines Compendium. Celgene Ltd. 1 August 2013. Retrieved 17 January 2014.
- "THALOMID® CAPSULES" (PDF). TGA eBusiness Services. Celgene Pty Limited. 21 June 2013. Retrieved 17 January 2014.
- The Myeloma Beacon Staff (8 April 2011). "FDA Announces Investigation Into Revlimid, Thalidomide, And Secondary Cancers". The Myeloma Beacon. Retrieved 17 January 2014.
- Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S et al. (August 2012). "Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance" (PDF). Blood 120 (8): 1597–1600. doi:10.1182/blood-2012-04-421883. PMC 3429303. PMID 22674807.
- "Thalidomide: risk of second primary malignancies". Medicines and Healthcare products Regulatory Agency. May 2013. Retrieved 17 January 2014.
- "Thalidomide drug label to warn of cancer risk". CBC News. May 22, 2013.
- Kim JH, Scialli AR (July 2011). "Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease" (PDF). Toxicological Sciences 122 (1): 1–6. doi:10.1093/toxsci/kfr088. PMID 21507989.
- Singhal S, Mehta J (February 2002). "Thalidomide in cancer". Biomedicine & Pharmacotherapy 56 (1): 4–12. doi:10.1016/S0753-3322(01)00146-9. PMID 11905508.
- Sarno EN, Grau GE, Vieira LM, Nery JA (April 1991). "Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states". Clin. Exp. Immunol. 84 (1): 103–8. doi:10.1111/j.1365-2249.1991.tb08131.x. PMC 1535359. PMID 2015700.
- Stephens TD, Bunde CJ, Fillmore BJ (June 2000). "Mechanism of action in thalidomide teratogenesis". Biochem. Pharmacol. 59 (12): 1489–99. doi:10.1016/S0006-2952(99)00388-3. PMID 10799645.
- D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). "Thalidomide is an inhibitor of angiogenesis". Proceedings of the National Academy of Sciences of the United States of America 91 (9): 4082–4085. Bibcode:1994PNAS...91.4082D. doi:10.1073/pnas.91.9.4082. PMC 43727. PMID 7513432.
- Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (May 2009). "Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation". Proc. Natl. Acad. Sci. U.S.A. 106 (21): 8573–8. Bibcode:2009PNAS..106.8573T. doi:10.1073/pnas.0901505106. JSTOR 40482723. PMC 2688998. PMID 19433787.
- Eriksson T, Björkman S, Roth B, Fyge A, Höglund P (1995). "Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide". Chirality 7 (1): 44–52. doi:10.1002/chir.530070109. PMID 7702998. Vancouver style error (help)
- Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G et al. (August 1996). "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity". J. Med. Chem. 39 (17): 3238–40. doi:10.1021/jm9603328. PMID 8765505.
- Man HW, Corral LG, Stirling DI, Muller GW (October 2003). "Alpha-fluoro-substituted thalidomide analogues". Bioorg. Med. Chem. Lett. 13 (20): 3415–7. doi:10.1016/S0960-894X(03)00778-9. PMID 14505639.
- Bartlett JB, Dredge K, Dalgleish AG (April 2004). "The evolution of thalidomide and its IMiD derivatives as anticancer agents". Nat. Rev. Cancer 4 (4): 314–22. doi:10.1038/nrc1323. PMID 15057291.
- Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H et al. (March 2009). "Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor". J. Med. Chem. 52 (6): 1522–4. doi:10.1021/jm900210d. PMID 19256507.
- Zimmer C (March 15, 2010). "Answers Begin to Emerge on How Thalidomide Caused Defects". New York Times. Retrieved 2010-03-21.
As they report in the current issue of Science, a protein known as cereblon latched on tightly to the thalidomide
- Mahony C, Erskine L, Niven J, Greig NH, Figg WD, Vargesson N (2013). "Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro". Proc. Natl. Acad. Sci. U.S.A. 110 (31): 12703–8. doi:10.1073/pnas.1307684110. PMC 3732931. PMID 23858438.
- Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R (2012). "Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide". Leukemia 26 (11): 2326–35. doi:10.1038/leu.2012.119. PMC 3496085. PMID 22552008.
- "Thalidomide chronology on Grünenthal Web site". Contergan.grunenthal.info. Retrieved 2013-05-22.[dead link]
- Thalidomide's Secret Past: The Link with Nazi Germany -Onco'Zine - The International Oncology Network (November 30, 2013)
- Franks ME, Macpherson GR, Figg WD (May 2004). "Thalidomide". Lancet 363 (9423): 1802–11. doi:10.1016/S0140-6736(04)16308-3. PMID 15172781.
- Moghe VV, Kulkarni U, Parmar UI (2008). "Thalidomide" (PDF). Bombay Hospital Journal (Bombay: Bombay Hospital) 50 (3): 473. Archived from the original on 22 July 2011.
- See Rouquette (1957) cited by Landesman-Dwyer S (1982). "Maternal drinking and pregnancy outcome". Appl Res Ment Retard 3 (3): 241–63. doi:10.1016/0270-3092(82)90018-2. PMID 7149705.
- Kelsey FO (1967). "Events after thalidomide". J. Dent. Res. 46 (6): 1201–5. doi:10.1177/00220345670460061201. PMID 5235007.
- Bundesverband Contergangeschädigter e.V (German Website; Last accessed on December 3, 2013)
- VFA: teratogenic effects 6. July 2011.
- page of Grünethal GmbH 3. July 2011
- Report on the website of the U.S. Food and Drug Administration
- Webb JF (November 1963). "Canadian Thalidomide Experience". Can Med Assoc J 89: 987–92. PMC 1921912. PMID 14076167.
- Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW et al. (1999). "Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis". J. Med. Chem. 42 (16): 3014–7. doi:10.1021/jm990083y. PMID 10447943.
- D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS (2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Seminars in Oncology 28 (6): 597–601. doi:10.1016/S0093-7754(01)90031-4. PMID 11740816.
- Rao KV (September 2007). "Lenalidomide in the treatment of multiple myeloma". Am J Health Syst Pharm 64 (17): 1799–807. doi:10.2146/ajhp070029. PMID 17724360.
- "Search of: pomalidomide". Clinicaltrials.gov. Retrieved 2012-09-01.
- Raghupathy R, Billett HH (March 2009). "Promising therapies in sickle cell disease". Cardiovasc Hematol Disord Drug Targets 9 (1): 1–8. doi:10.2174/187152909787581354. PMID 19275572.
- "Pomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Retrieved 2013-08-10.
- "Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Retrieved 2013-08-10.
- "Thalidomide Celgene : EPAR - Product Information" (PDF). European Medicines Agency. Celgene Europe Limited. 29 August 2013. Retrieved 19 January 2014.
- Lewis, R (26 November 2013). "Thalidomide Induced Remission in Early-Onset Crohn's Disease". Medscape Medical News. WebMD. Retrieved 19 January 2014.
- Franks ME, Macpherson GR, Figg WD (May 2004). "Thalidomide". Lancet 363 (9423): 1802–1811. doi:10.1016/S0140-6736(04)16308-3. PMID 15172781.
- Okafor, MC (2003). "Thalidomide for Erythema Nodosum Leprosum and Other Applications". Medscape Medical News. WebMD. Retrieved 19 January 2014.
- Waters MF (March 1971). "An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum". Leprosy Review 42 (1): 26–42. PMID 4338720.
- Villahermosa LG, Fajardo TT, Abalos RM, Balagon MV, Tan EV, Cellona RV et al. (May 2005). "A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum" (PDF). The American Journal of Tropical Medicine and Hygiene 72 (5): 518–526. PMID 15891124.
- Rose, LJ; Fishman, AD; Sparano, JA (11 March 2013). Talavera, F; McKenna, R; Harris, JE, ed. "Kaposi Sarcoma Treatment & Management". Medscape Reference. WebMD. Retrieved 19 January 2014.
- Bren L (2001-02-28). "Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History". FDA Consumer (U.S. Food and Drug Administration). Retrieved 2009-12-23.
- "Turning Points of History–Prescription for Disaster". History Television. Retrieved 24 February 2010.[dead link]
- "Apology for thalidomide survivors". BBCNews:Health (BBC News). 14 January 2010. Retrieved 2010-01-14.
- Anon. "Widukind Lenz". who name it?. Ole Daniel Enersen. Retrieved 2009-05-01.
- Anon (2002-06-07). "Thalidomide:40 years on". BBC news (BBC). Retrieved 2009-05-01.
- "Report of Thalidomide at University of New South Wales". Embryology.med.unsw.edu.au. Retrieved 2012-12-30.
- "DDR-Bürger schliefen ohne Contergan" [East German citizens slept without thalidomide]. Neues Deutschland (in German). 4 November 2007. Retrieved Jun 6, 2013.
- Thomann, Klaus-Dieter (2007). "Die Contergan-Katastrophe: Die trügerische Sicherheit der "harten" Daten" [The thalidomide disaster: The false security of 'hard' data]. Deutsches Ärzteblatt (in German) 104 (41): A–2778 / B–2454 / C–2382. Archived from the original on December 6, 2011. Retrieved June 6, 2013.
- Die Contergankatastrophe: Eine Bilanz Nach 40 Jahren, Ludwig Zichner, Michael A. Rauschmann, Klaus-Dieter Thomann, Gabler Wissenschaftsverlage, 2005 – 190 Seiten
- "10.000 Fälle von Missbildungen" [10,000 cases of malformations] (in German). ORF. Retrieved June 6, 2013.
- Mekdeci, Betty. "Bendectin Part 1 (PDF link) How a Commonly Used Drug Caused Birth Defects".
- "The Public's Quiet Savior From Harmful Medicines". The New York Times. 13 September 2010.
- Ryan, Caroline (1 April 2004). "They just didn't know what it would do". BBC News:Health (BBC news). Retrieved 2009-05-01.
- Flintoff, John-Paul (March 23, 2008). "Thalidomide: the battle for compensation goes on". The Sunday Times (London: Times Newspapers Ltd.). Retrieved 2009-05-01.
- "Compensation offer on Thalidomide". BBC News. 7 July 2005. Retrieved 26 July 2011.
- "Thalidomide survivors to get £20m". BBC News. 23 December 2009. Retrieved 26 July 2011.
- "Australian thalidomide victims win right for hearing". ABC News. 19 December 2011.
- Speech on the occasion of the inauguration of Thalidomide-Memorial; Grünenthal GmbH Website (Last accessed on December 3, 2013)
- "Thalidomide apology insulting, campaigners say". BBC News. September 1, 2012.
- Warren R (2001). "Living in a World With Thalidomide: A Dose of Reality". FDA Consumer 35 (2): 40. PMID 11444250.
- Racz WJ, Ecobichon DJ, Baril M (August 2003). "On-line sources of toxicological information in Canada". Toxicology 190 (1–2): 3–14. doi:10.1016/S0300-483X(03)00192-6. PMID 12909394.
- "Orpheus lives: A small good thing in Quastoff". The Portland Phoenix. April 19, 2002. Retrieved June 6, 2013.
- "NoBody's Perfect (2008): Release Info". IMDB. Retrieved June 6, 2013.
- Brussat, Frederic; Brussat, Mary Ann. "Film Review: NoBody's Perfect". Spirituality & Practice. Retrieved June 6, 2013.
- "50 Years: The Kefauver-Harris Amendments". Food and Drug Administration (United States). Retrieved 6 June 2013.
- "Thalidomide". National Health Service (England). Retrieved 6 June 2013.
- Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM (April 2005). "Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial" (PDF). GUT 54 (4): 540–545. doi:10.1136/gut.2004.047563. PMC 1774430. PMID 15753541.
- Sharpstone D, Rowbottom A, Francis N, Tovey G, Ellis D, Barrett M et al. (June 1997). "Thalidomide: a novel therapy for microsporidiosis". Gastroenterology 112 (6): 1823–1829. doi:10.1053/gast.1997.v112.pm9178672. PMID 9178672.
- Tunio MA, Hashmi A, Qayyum A, Naimatullah N, Masood R (September 2012). "Low-dose thalidomide in patients with metastatic renal cell carcinoma". Journal of the Pakistan Medical Association 62 (9): 876–879. PMID 23139966.
- Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S et al. (March 1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet Syndrome: a randomized, double-blind, placebo-controlled trial". Annals of Internal Medicine 128 (6): 443–450. doi:10.7326/0003-4819-128-6-199803150-00004. PMID 9499327.
- Stephens, Trent; Brynner, Rock (2001-12-24). Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine. Perseus Books. ISBN 0-7382-0590-7.
- Knightley, Phillip; Evans, Harold (1979). Suffer The Children: The Story of Thalidomide. New York: The Viking Press. ISBN 0-670-68114-8.
- Rouhi, Maureen (2005). "Thalidomide". Chemical & Engineering News 83 (25): 122. doi:10.1021/cen-v083n025.p122 (inactive 2015-01-09). Archived from the original on February 13, 2010. Retrieved June 6, 2013.
-  (Needs registration)
- on Thalidomide
- Thalidomide — Annotated List of Links (covering English and German pages)
- WHO Pharmaceuticals Newsletter No. 2, 2003 – See page 11, Feature Article
- GmbH — Thalidomide
- Celgene website on Thalomid
- The Return of Thalidomide — BBC
- CBC Digital Archives – Thalidomide: Bitter Pills, Broken Promises
- Thalidomide UK
- The Thalidomide Trust
- The International Contergan Thalidomide Alliance website
- "The Big Pitch: How would you conduct a campaign for the new Thalidomide Drugs?", forum of pharmaceutical and medical marketing professionals commenting on how they would address the thalidomine controversies.
- The 50-year global cover-up